Top

Published in:

01-07-2015 | Research Article

Association between ABO gene polymorphism (rs505922) and cancer risk: a meta-analysis

Authors: Yun-Fei Duan, Feng Zhu, Xiao-Dong Li, Yong An, Hanze Zhang, Yebin Zhou, Xiaofei Zhang, Yong Jiang

Published in: Tumor Biology | Issue 7/2015

Abstract

Previous studies have showed that ABO blood type is associated with multiple gastrointestinal cancers, including pancreatic cancer. Recently, one single nucleotide polymorphism (SNP) rs505922 in ABO gene has been implicated in susceptibility to pancreatic cancer across different populations, but different results were found in other types of cancer. This meta-analysis aimed to clarify the association. All eligible case–control studies were identified by searching through PubMed and Chinese language databases (CNKI and WanFang) up to September 1, 2014. Pooled estimates (odds ratio) were used to assess the strength of associations in fixed- or random-effects models. A total of nine studies with 10,304 cases and 15,564 controls were included. Overall, SNP rs505922 C allele was confirmed as a risk factor for cancer. Additionally, in further stratified analysis by cancer type, C allele carriers were more likely to have higher risk of pancreatic cancer. This study provided evidence of SNP rs505922 C allele as a strong risk factor of cancer susceptibility, specifically for pancreatic cancer.

Petersen GM, Amundadottir L, Fuchs CS, Kraft P, Stolzenberg-Solo mon RZ, Jacobs KB, et al. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet. 2010;42:224–8.CrossRefPubMedPubMedCentral

Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, Fuchs CS, Petersen GM, Arslan AA, et al. Genome-wide association study identifies variants in the abo locus associated with susceptibility to pancreatic cancer. Nat Genet. 2009;41:986–90.CrossRefPubMedPubMedCentral

Reid ME, Mohandas N. Red blood cell blood group antigens: structure and function. Semin Hematol. 2004;41:93–117.CrossRefPubMed

Aird I, Bentall HH, Roberts JA. A relationship between cancer of stomach and the ABO blood groups. Br Med J. 1953;1:799–801.CrossRefPubMedPubMedCentral

Aird I, Lee DR, Roberts JA. ABO blood groups and cancer of oesophagus, cancerof pancreas, and pituitary adenoma. Br Med J. 1960;1:1163–6.CrossRefPubMedPubMedCentral

Melzer D, Perry JR, Hernandez D, Corsi AM, Stevens K, Rafferty I, et al. A genome-wide association study identifies protein quantitative trait loci (pqtls). PLoS Genet. 2008;4:e1000072.CrossRefPubMedPubMedCentral

Liumbruno GM, Franchini M. Hemostasis, cancer, and abo blood group: the most recent evidence of association. J Thromb Thrombolysis. 2014;38:160–6.CrossRefPubMed

Pare G, Chasman DI, Kellogg M, Zee RY, Rifai N, Badola S, et al. Novel association of abo histo-blood group antigen with soluble icam-1: results of a genome-wide association study of 6,578 women. PLoS Genet. 2008;4:e1000118.CrossRefPubMedPubMedCentral

Yuan X, Waterworth D, Perry JR, Lim N, Song K, Chambers JC, et al. Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am J Hum Genet. 2008;83:520–8.CrossRefPubMedPubMedCentral

10.

Souto JC, Almasy L, Muniz-Diaz E, Soria JM, Borrell M, Bayen L, et al. Functional effects of the abo locus polymorphism on plasma levels of von willebrand factor, factor VIII, and activated partial thromboplastin time. Arterioscler Thromb Vasc Biol. 2000;20:2024–8.CrossRefPubMed

11.

Itzkowitz SH, Yuan M, Ferrell LD, Ratcliffe RM, Chung YS, Satake K, et al. Cancer-associated alterations of blood group antigen expression in the human pancreas. J Natl Cancer Inst. 1987;79:425–34.PubMed

12.

Ishijima N, Suzuki M, Ashida H, Ichikawa Y, Kanegae Y, Saito I, et al. Baba-mediated adherence is a potentiator of the helicobacter pylori type iv secretion system activity. J Biol Chem. 2011;286:25256–64.CrossRefPubMedPubMedCentral

13.

Trikudanathan G, Philip A, Dasanu CA, Baker WL. Association between helicobacter pylori infection and pancreatic cancer. A cumulative meta-analysis. JOP. 2011;12:26–31.PubMed

14.

Wang DS, Chen DL, Ren C, Wang ZQ, Qiu MZ, Luo HY, et al. ABO blood group, hepatitis b viral infection and risk of pancreatic cancer. Int J Cancer J Int Cancer. 2012;131:461–8.CrossRef

15.

Duell EJ, Bonet C, Munoz X, Lujan-Barroso L, Weiderpass E, Boutron-Ruault MC, Racine A, Severi G, Canzian F, Rizzato C, Boeing H, Overvad K, Tjonneland A, Arguelles M, Sanchez-Cantalejo E, Chamosa S, Huerta JM, Barricarte A, Khaw KT, Wareham N, Travis RC, Trichopoulou A, Trichopoulos D, Yiannakouris N, Palli D, Agnoli C, Tumino R, Naccarati A, Panico S, Bueno-de-Mesquita HB, Siersema PD, Peeters PH, Ohlsson B, Lindkvist B, Johansson I, Ye W, Johansson M, Fenger C, Riboli E, Sala N, Gonzalez CA. Variation at abo histo-blood group and FUT loci and diffuse and intestinal gastric cancer risk in a european population. Int J Cancer J Int Cancer. 2014;136(4):880-93.

16.

Gates MA, Xu M, Chen WY, Kraft P, Hankinson SE, Wolpin BM. ABO blood group and breast cancer incidence and survival. Int J Cancer J Int Cancer. 2012;130:2129–37.CrossRef

17.

Krawczyk M, Mihalache F, Hoblinger A, Acalovschi M, Lammert F, Zimmer V. Pancreatic cancer risk variant abo rs505922 in patients with cholangiocarcinoma. World J Gastroenterol WJG. 2011;17:4640–2.CrossRefPubMed

18.

Poole EM, Gates MA, High BA, Chanock SJ, Cramer DW, Cunningham JM, et al. ABO blood group and risk of epithelial ovarian cancer within the ovarian cancer association consortium. Cancer Causes Control CCC. 2012;23:1805–10.CrossRefPubMedPubMedCentral

19.

Rizzato C, Campa D, Pezzilli R, Soucek P, Greenhalf W, Capurso G, et al. ABO blood groups and pancreatic cancer risk and survival: results from the PANcreatic Disease ReseArch (PANDoRA) consortium. Oncol Rep. 2013;29:1637–44.PubMed

20.

Willis JA, Olson SH, Orlow I, Mukherjee S, McWilliams RR, Kurtz RC, et al. A replication study and genome-wide scan of single-nucleotide polymorphisms associated with pancreatic cancer risk and overall survival. Clin Cancer Research Off J Am Assoc Cancer Res. 2012;18:3942–51.CrossRef

21.

Wolpin BM, Kraft P, Gross M, Helzlsouer K, Bueno-de-Mesquita HB, Steplowski E, et al. Pancreatic cancer risk and abo blood group alleles: results from the pancreatic cancer cohort consortium. Cancer Res. 2010;70:1015–23.CrossRefPubMedPubMedCentral

22.

Xu HL, Cheng JR, Zhang W, Wang J, Yu H, et al. Re-evaluation of ABO gene polymorphisms detected in a genome-wide association study and risk of pancreatic ductal adenocarcinoma in a Chinese population. Chin J Cancer. 2014;33:68–73.

23.

Duell EJ, Bonet C, Munoz X, Lujan-Barroso L, Weiderpass E, et al. Variation at ABO histo-blood group and FUT loci and diffuse and intestinal gastric cancer risk in a European population. Int J Cancer. 2014;136(4):880–893.

24.

Gates MA, Xu M, Chen WY, Kraft P, Hankinson SE, et al. ABO blood group and breast cancer incidence and survival. Int J Cancer. 2012;130:2129–2137.

25.

Krawczyk M, Mihalache F, Hoblinger A, Acalovschi M, Lammert F, et al. Pancreatic cancer risk variant ABO rs505922 in patients with cholangiocarcinoma. World J Gastroenterol. 2011;17:4640–4642.

26.

Poole EM, Gates MA, High BA, Chanock SJ, Cramer DW, et al. ABO blood group and risk of epithelial ovarian cancer within the Ovarian Cancer Association Consortium. Cancer Causes Control. 2012;23:1805–1810.

27.

Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127:820–826.

28.

Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–1558.

29.

Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–748.

30.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188.

31.

Begg CB, Mazumdar M.(1994) Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–1101.

32.

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634.

33.

Rizzato C, Campa D, Pezzilli R, Soucek P, Greenhalf W, et al. ABO blood groups and pancreatic cancer risk and survival: results from the PANcreatic Disease ReseArch (PANDoRA) consortium. Oncol Rep. 2013;29:1637–1644.

34.

Willis JA, Olson SH, Orlow I, Mukherjee S, McWilliams RR, et al. A replication study and genomewide scan of single-nucleotide polymorphisms associated with pancreatic cancer risk and overall survival. Clin Cancer Res. 2012;18:3942–3951.

35.

Wolpin BM, Kraft P, Gross M, Helzlsouer K, Bueno-de-Mesquita HB, et al. Pancreatic cancer risk and ABO blood group alleles: results from the pancreatic cancer cohort consortium. Cancer Res. 2010;70:1015–1023.

Title: Association between ABO gene polymorphism (rs505922) and cancer risk: a meta-analysis
Authors: Yun-Fei Duan
Feng Zhu
Xiao-Dong Li
Yong An
Hanze Zhang
Yebin Zhou
Xiaofei Zhang
Yong Jiang
Publication date: 01-07-2015
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 7/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-3159-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2015

CHRNA3 genetic polymorphism and the risk of lung cancer in the Chinese Han smoking population

IL-6 originated from breast cancer tissue-derived mesenchymal stromal cells may contribute to carcinogenesis

Serum C-reactive protein and overall survival of patients with osteosarcoma

EMMPRIN in gynecologic cancers: pathologic and therapeutic aspects

The effect of statins on cancer cells—review

miR-342-3p targets RAP2B to suppress proliferation and invasion of non-small cell lung cancer cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer